Wednesday, March 9, 2022
8:53 AM EST – Oncolytics Biotech Inc : Today announces phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma. The data are featured in an abstract accepted for a poster presentation at the upcoming American Association for Cancer Research Annual Meeting, which is taking place both virtually and in-person April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The abstract is also posted on the AACR meeting website. Oncolytics Biotech Inc (T.ONC) shares were up $0.05 at 2.02.
Stocks in Play: Oncolytics Biotech Inc, Wed, 09 Mar 2022 08:57:07 EST